Lantheus Holdings, Inc. (LNTH): Depreciation & Amortization
$70.10M
Year ended 2025-12-31
$88.51M
Trailing 12 months to 2026-06-30
+13.5%
3-year compound annual growth
+23.2%
5-year compound annual growth
+13.6%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $70.10M | +8.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $64.62M | +7.6% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $60.04M | +25.3% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $47.93M | +13.3% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $42.29M | +71.3% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $24.69M | +84.5% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $13.38M | -3.9% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $13.93M | -27.6% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $19.23M | +5.3% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $18.26M | -7.1% | 2019-02-20, From 2016-01-01 |
| 2015-12-31 | $19.65M | +3.3% | 2018-02-26, From 2015-01-01 |
| 2014-12-31 | $19.02M | n/a | 2017-02-23, From 2014-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $70.10M | +8.5% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $442.00M | -2.5% |
| Neogen Corp (NEOG) | 2026-05-31 | $116.30M | -2.7% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $53.70M | -12.3% |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $145.18M | +11.7% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $9.77M | -5.0% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $6.34M | -3.6% |
| Immucell Corp (ICCC) | 2025-12-31 | $2.78M | +2.0% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $112.0K | +21.7% |
Compare LNTH, QDEL, NEOG, MYGN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗